Close



May 17, 2022 07:00AM
Apr 26, 2022 08:00AM
Apr 26, 2022 08:00AM
Mar 8, 2022 08:00AM
Nov 15, 2021 07:30AM
Sep 17, 2021 07:01AM
Sep 17, 2021 07:00AM VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
Aug 30, 2021 09:24AM
Aug 30, 2021 07:01AM
Aug 30, 2021 07:00AM
Aug 16, 2021 07:00AM
Jun 15, 2021 07:03AM
Jun 15, 2021 07:00AM
Jun 3, 2021 07:00AM VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
Apr 9, 2021 09:31AM
Apr 8, 2021 05:45PM
Nov 16, 2020 07:00AM
Oct 12, 2020 07:13AM
Oct 12, 2020 07:00AM
Sep 8, 2020 08:09AM
Sep 8, 2020 08:00AM VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
Aug 13, 2020 07:00AM
Feb 20, 2020 08:19AM
Feb 20, 2020 08:00AM
Jan 8, 2020 08:04AM
Jan 8, 2020 08:00AM
Nov 14, 2019 07:00AM
Nov 6, 2019 08:07AM VBL Therapeutics (VBLT) Announces New IND for Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma
Nov 6, 2019 08:00AM
Nov 16, 2018 07:04AM
Nov 16, 2018 07:00AM
Mar 8, 2018 06:16AM
Mar 8, 2018 06:00AM
Feb 8, 2018 07:29AM
Feb 8, 2018 07:00AM VBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan
Jan 3, 2018 07:05AM
Dec 27, 2017 07:01AM
Dec 27, 2017 07:00AM
Dec 18, 2017 08:28AM
Nov 21, 2017 08:00AM
Nov 17, 2017 09:27AM
Nov 17, 2017 09:01AM VBL Therapeutics (VBLT) Prices 2.5M Share Offering at $7.5/Sh
Nov 17, 2017 09:00AM
Nov 16, 2017 04:02PM
Nov 16, 2017 04:01PM
Nov 14, 2017 07:00AM
Nov 9, 2017 08:00AM
Nov 7, 2017 10:29AM
Nov 6, 2017 09:24AM Pre-Open Movers 11/06: (TXMD) (VBLT) (CAVM) Higher; (S) (TMUS) (VZ) Lower (more...)
Nov 6, 2017 07:17AM

251,761 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All